<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695275</url>
  </required_header>
  <id_info>
    <org_study_id>BCH Lung 013</org_study_id>
    <nct_id>NCT04695275</nct_id>
  </id_info>
  <brief_title>Clinical Feature and Microbiology Characteristics of Empyema in Children</brief_title>
  <official_title>A Multicenter Observational Study About the Clinical Feature and Microbiology Characteristics of Empyema in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capital Institute of Pediatrics, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital affiliated with Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Hebei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baoding Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to clarify the clinical characteristics and reversion of children with&#xD;
      empyema, observe the effect of streptococcus vaccine application on serotype of&#xD;
      streptococcus, and to explore the susceptibility factors of streptococcus empyema in children&#xD;
      in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Empyema is a major complication of bacterial community-acquired pneumonia in children. And&#xD;
      studies have shown that although the incidence of community-acquired pneumonia in children&#xD;
      has decreased with the application of pneumococcal conjugate vaccine, the incidence of&#xD;
      empyema has increased, which raises the difficulty to disease treatment, and aggravates the&#xD;
      financial burden on medical care.&#xD;
&#xD;
      Streptococcus is one of the most common pathogens causing children's empyema. In recent&#xD;
      years, although more and more researches are reported on children's community- acquired&#xD;
      pneumonia or pleural effusion, the clinical studies on streptococcus pneumoniae empyema are&#xD;
      rarely mentioned. Therefore, a multicenter observational study is needed to better understand&#xD;
      the clinical characteristics and reversion of children with empyema, observe the effect of&#xD;
      streptococcus vaccine application on serotype of streptococcus, and explore the&#xD;
      susceptibility factors of streptococcus empyema in children in China. The study mentioned&#xD;
      above will contribute to optimize the treatment strategy of streptococcus empyema for the&#xD;
      future, and reduce the incidence of children's empyema.&#xD;
&#xD;
      The trial will be completed in 3 years with 100 participants taken from hospitals in&#xD;
      partnership with clinical research collaboration of National Clinical Research Center for&#xD;
      Respiratory Diseases, China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 6, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The cure rate of empyema</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The improvement rate of empyema.</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of long-term adverse outcomes.</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>4weeks</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of respiratory symptoms</measure>
    <time_frame>4weeks</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>4weeks</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.</measure>
    <time_frame>4weeks</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of streptococcus pneumoniae empyema</measure>
    <time_frame>10 months</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype distribution of children with streptococcus pneumoniae empyema</measure>
    <time_frame>10 months</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccination rate of pneumococcal conjugate vaccine</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Empyema</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are aged 1day to 18 years, and diagnosed with &quot;pneumonia combined with&#xD;
        empyema&quot;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 1 day to 18 years&#xD;
&#xD;
          -  Admitted with diagnosis of pneumonia combined with pleural effusion&#xD;
&#xD;
          -  The appearance of thoracic fluid or the results of fluid examination conforms to&#xD;
             empyema with at least 1 of the following criteria:&#xD;
&#xD;
               -  Thoracentesis is pus.&#xD;
&#xD;
               -  Thoracic fluid smear observation show bacterial-positive.&#xD;
&#xD;
               -  Thoracic fluid culture test show bacterial-positive.&#xD;
&#xD;
               -  Cell counting of thoracic fluid is more than 10x109/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded if the thoracic fluids are caused by non-infectious factors,&#xD;
             such as cardiovascular, connective tissue disease, tumor or trauma, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Children's Hospital,</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Baoping Xu</last_name>
      <phone>8659616309</phone>
      <email>xubaopingbch@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 3, 2021</last_update_submitted>
  <last_update_submitted_qc>January 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Children's Hospital</investigator_affiliation>
    <investigator_full_name>Baoping XU</investigator_full_name>
    <investigator_title>Director of China National Clinical Research Center for Respiratory Diseases, Chief of Respiratory Department</investigator_title>
  </responsible_party>
  <keyword>Empyema</keyword>
  <keyword>streptococcus</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empyema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

